Bristol Myers' latest campaign for combo drug Opdualag emphasizes that the two immunotherapies work 'side by side.'
Bristol Myers debuts first Opdualag campaign, adds to its two-combo cancer drug marketing
Bristol Myers Squibb’s first campaign for Opdualag marks a second stake in the ground for the biopharma. The new work is its second immuno-oncology combo …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
